This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Maja Janas De Angelis, PhD, DABT
Associate Director, Investigative Toxicology at Alnylam Pharmaceuticals at Alnylam Pharmaceuticals

Profile

Maja Janas De Angelis, PhD, DABT is currently an Associate Director, Investigative Toxicology, at Alnylam Pharmaceuticals. She earned her Bachelor of Arts in Chemistry and Biochemistry from the University of Colorado in 2007, and her PhD in Biological and Biomedical Sciences from Harvard University in 2012, working with Dr. Carl D. Novina on novel regulators of microRNA biogenesis and function. After completing her PhD, Dr. Janas De Angelis accepted a position as Presidential Postdoctoral Fellow in the RNAi Therapeutics group at Novartis Institutes for BioMedical Research, working on mechanisms of selective microRNA export via exosomes and novel roles of double-stranded RNA binding proteins in microRNA and siRNA pathways. In 2014, Dr. Janas De Angelis joined the Investigative Toxicology group at Alnylam Pharmaceuticals, where she is championing a variety of investigative, molecular mechanism-based research efforts related to preclinical safety evaluation of RNAi therapeutics.

Agenda Sessions

  • Identifying and Avoiding RISC Mediated Off-Target Events

    9:30am